首页> 外文OA文献 >Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers

【2h】

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers

机译：口服CP-868,596（一种高度特异性的血小板衍生生长因子受体酪氨酸激酶抑制剂）在晚期癌症中的安全性，耐受性和药代动力学的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lewis, Nancy L.; Lewis, Lionel D.; Eder, Joseph P.; Reddy, Nandi J.; Guo, Feng; Pierce, Kristen J.; Olszanski, Anthony J.; Cohen, Roger B.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. [J] . Lewis NL, Lewis LD, Eder JP Journal of Clinical Oncology . 2009,第31期

机译：口服CP-868,596（一种高度特异性的血小板源性生长因子受体酪氨酸激酶抑制剂）在晚期癌症患者中的安全性，耐受性和药代动力学的I期研究。
2. 585 POSTER Phase I study of the safety and pharmacokinetics of an oral, film-coated (FC) tablet of CP-868,596, a PDGFR inhibitor, in patients with advanced cancers [J] . L.Lewis, N.Reddy, F.Guo, European Journal of Cancer Supplements . 2008,第12期

机译：585 POSTER I期研究PDGFR抑制剂CP-868,596的口服薄膜衣（FC）片剂在晚期癌症患者中的安全性和药代动力学
3. 585 POSTER Phase I study of the safety and pharmacokinetics of an oral, film-coated (FC) tablet of CP-868,596, a PDGFR inhibitor, in patients with advanced cancers [J] . L.Lewis, N.Reddy, F.Guo, European Journal of Cancer Supplements . 2008,第12期

机译：585 POSTER I期研究PDGFR抑制剂CP-868,596的口服薄膜衣（FC）片剂在晚期癌症患者中的安全性和药代动力学
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Phase I Study of the Safety Tolerability and Pharmacokinetics of Oral CP-868596 a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers [O] . Nancy L. Lewis, Lionel D. Lewis, Joseph P. Eder, -1

机译：口服CP-868596（一种高度特异性的血小板衍生生长因子受体酪氨酸激酶抑制剂）在晚期癌症中的安全性耐受性和药代动力学的I期研究
7. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors [O] . 2012

机译：达可替尼（PF-00299804）的I期和药代动力学研究，它是一种口服不可逆的人类表皮生长因子受体-1，-2和-4酪氨酸激酶的小分子抑制剂，用于患有晚期实体瘤的日本患者

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers

著录项

引文网络

相似文献

相关主题

期刊订阅